Eli Lilly is tackling a high-growth market: weight loss. The company’s weight loss portfolio brought in $10 billion in the ...

Strive Compounding Pharmacy alleges the two pharma companies are coordinating an effort to restrict compounded access.

GLP-1 agonist injections, although originally developed to treat type 2 diabetes, have changed how we approach obesity.1 The two main types now in use—semaglutide (Wegovy), produced by Novo Nordisk, ...

After a lackluster first half of 2025, healthcare stocks staged a comeback, posting the best performance among the 11 S&P 500 ...

Despite ushering in the current GLP-1 era, Novo Nordisk has fallen behind its chief rival Eli Lilly, which has exceeded the ...

A single-judge bench of Delhi high court had allowed Dr Reddy’s to continue manufacturing and exporting semaglutide to ...

Once exclusively a treatment for diabetes, GLP-1 medications have gone mainstream — forcing restaurants to adjust to changing ...

NVO shares jump 9.1% as early U.S. prescriptions for oral Wegovy show strong first-week demand after its early January launch ...

For the quarter ended December 31, 2025, the SMA outperformed the Index on both a gross- and net-of-fees basis due to ...